Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H18N2O4 |
Molecular Weight | 218.2502 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCC(C)(COC(N)=O)COC(N)=O
InChI
InChIKey=NPPQSCRMBWNHMW-UHFFFAOYSA-N
InChI=1S/C9H18N2O4/c1-3-4-9(2,5-14-7(10)12)6-15-8(11)13/h3-6H2,1-2H3,(H2,10,12)(H2,11,13)
DescriptionSources: https://www.drugs.com/monograph/meprobamate.htmlCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9067327 |
https://www.ncbi.nlm.nih.gov/pubmed/6128137 |
http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/meprobamate_107/WC500120737.pdf
Sources: https://www.drugs.com/monograph/meprobamate.html
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9067327 |
https://www.ncbi.nlm.nih.gov/pubmed/6128137 |
http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/meprobamate_107/WC500120737.pdf
Meprobamate is a carbamate derivative used as an anxiolytic drug. Meprobamate enhances GABA-A currents, and at higher concentration, exhibits a separate channel-blocking effect that limits the magnitude of GABA(A) receptor potentiation. It is also a potent adenosine reuptake inhibitor (AdoRI), which is most likely responsible for its lesser degree of sedation compared to barbiturates. Meprobamate was withdrawn from European and Canadian markets due to its potential to cause physical and psychological dependence.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9067327 |
|||
Target ID: CHEMBL1997 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6128137 |
55.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.drugs.com/pro/meprobamate.html |
Primary | MILTOWN Approved UseMeprobamate tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually do not require treatment with an anxiolytic. The effectiveness of meprobamate tablets in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. Launch Date1955 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
18.4 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7974621 |
700 mg single, oral dose: 700 mg route of administration: Oral experiment type: SINGLE co-administered: |
MEPROBAMATE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1.8 μg/mL |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
MEPROBAMATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.5 μg/mL |
350 mg single, oral dose: 350 mg route of administration: Oral experiment type: SINGLE co-administered: |
MEPROBAMATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
32 μg × h/mL |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
MEPROBAMATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
46 μg × h/mL |
350 mg single, oral dose: 350 mg route of administration: Oral experiment type: SINGLE co-administered: |
MEPROBAMATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
9.7 h |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
MEPROBAMATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
9.6 h |
350 mg single, oral dose: 350 mg route of administration: Oral experiment type: SINGLE co-administered: |
MEPROBAMATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
76% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7974621 |
700 mg single, oral dose: 700 mg route of administration: Oral experiment type: SINGLE co-administered: |
MEPROBAMATE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | likely (co-administration study) Comment: co-administration of CYP2C19 inhibitors, such as omeprazole or fluvoxamine, could result in increased exposure of carisoprodol and decreased exposure of meprobamate Sources: https://www.ncbi.nlm.nih.gov/books/NBK425390/ |
PubMed
Title | Date | PubMed |
---|---|---|
Identification of three novel mutations in the USH1C gene and detection of thirty-one polymorphisms used for haplotype analysis. | 2001 |
|
Marked differences between metalloproteases meprin A and B in substrate and peptide bond specificity. | 2001 Apr 20 |
|
Internet-based prescription of sildenafil: a 2104-patient series. | 2001 Jan-Mar |
|
The fate of neurotization techniques on reinnervation after denervation of the gastrocnemius muscle: an experimental study. | 2001 Jul |
|
Multimeric structure of the secreted meprin A metalloproteinase and characterization of the functional protomer. | 2001 Jun 22 |
|
Accuracy and precision of computer models to predict passage of crude protein and amino acids to the duodenum of lactating cows. | 2001 Mar |
|
Myosin VIIa, harmonin and cadherin 23, three Usher I gene products that cooperate to shape the sensory hair cell bundle. | 2002 Dec 16 |
|
Probing the active sites and mechanisms of rat metalloproteases meprin A and B. | 2002 Jul-Aug |
|
Zinc ligands in an astacin family metalloprotease meprin A. | 2002 Jul-Aug |
|
Nonsyndromic recessive deafness DFNB18 and Usher syndrome type IC are allelic mutations of USHIC. | 2002 Jun |
|
Impact of in utero exposure to EtOH on corpus callosum development and paw preference in rats: protective effects of silymarin. | 2002 Nov 11 |
|
Degeneration of the intervertebral disc. | 2003 |
|
Sodium loading changes urinary protein excretion: a proteomic analysis. | 2003 Jun |
|
Neurovascular congruence results from a shared patterning mechanism that utilizes Semaphorin3A and Neuropilin-1. | 2003 Mar 1 |
|
Differential distribution of harmonin isoforms and their possible role in Usher-1 protein complexes in mammalian photoreceptor cells. | 2003 Nov |
|
ProMate: a structure based prediction program to identify the location of protein-protein binding sites. | 2004 Apr 16 |
|
Transport of meprin subunits through the secretory pathway: role of the transmembrane and cytoplasmic domains and oligomerization. | 2004 Aug 13 |
|
Anatomical organization of motoneurons and interneurons in the mudpuppy (Necturus maculosus) brachial spinal cord: the neural substrate for central pattern generation. | 2004 Aug-Sep |
|
Kinetics and rhythm of body contractions in the sponge Tethya wilhelma (Porifera: Demospongiae). | 2004 Dec |
|
HTLV-1 and -2 envelope SU subdomains and critical determinants in receptor binding. | 2004 Dec 2 |
|
Human meprin alpha and beta homo-oligomers: cleavage of basement membrane proteins and sensitivity to metalloprotease inhibitors. | 2004 Mar 1 |
|
Selective disruption of the E-cadherin-catenin system by an algal toxin. | 2004 Mar 8 |
|
Aneural culture of rat myoblasts for myocardial transplant. | 2004 May |
|
Harp (harmonin-interacting, ankyrin repeat-containing protein), a novel protein that interacts with harmonin in epithelial tissues. | 2004 Oct |
|
Dietary phosphorus-responsive genes in the intestine, pyloric ceca, and kidney of rainbow trout. | 2004 Sep |
|
Genetic heterogeneity in Usher syndrome. | 2004 Sep 15 |
|
Sequence and structural analysis of BTB domain proteins. | 2005 |
|
Inhibitors of polyamine biosynthesis decrease the expression of the metalloproteases meprin alpha and MMP-7 in hormone-independent human breast cancer cells. | 2005 |
|
Indigo carmine for the selective endoscopic intervertebral nuclectomy. | 2005 Aug |
|
[Usher syndrome type I and the differentiation of inner ear sensory cells' hair bundles]. | 2005 Aug-Sep |
|
The molecular immunology of mucositis: implications for evidence-based research in alternative and complementary palliative treatments. | 2005 Dec |
|
Interactions in the network of Usher syndrome type 1 proteins. | 2005 Feb 1 |
|
Meprin metalloprotease expression and regulation in kidney, intestine, urinary tract infections and cancer. | 2005 Jun 13 |
|
BMP-6 inhibits growth of mature human B cells; induction of Smad phosphorylation and upregulation of Id1. | 2005 May 9 |
|
Stimulation of poliovirus RNA synthesis and virus maturation in a HeLa cell-free in vitro translation-RNA replication system by viral protein 3CDpro. | 2005 Nov 21 |
|
Generation of biologically active interleukin-1beta by meprin B. | 2005 Sep 7 |
|
Analysis of prion strains by PrPSc profiling in sporadic Creutzfeldt-Jakob disease. | 2006 Feb |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/monograph/meprobamate.html
Meprobamate is administered orally. The smallest effective individual doses should be used to avoid oversedation. Typical dose is 1.2–1.6 g daily in 3 or 4 divided doses.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9067327
All electrophysiological recordings were conducted on the stage of a Nikon Diaphot inverted phase contrast microscope at room temperature (23–25°C). Currents were monitored with either an Axopatch 1B or 200A patch clamp amplifier. Voltages corresponding to the currents were acquired with a high-speed chart recorder, and digitized for off-line analysis with the Axotape software package. The holding potential for whole-cell recordings was −60 mV unless otherwise noted. Drugs were dissolved in buffer on the day of use and applied via a nine-barrel rapid perfusion system in which all barrels (320 μm outer diameter quartz tubes; J & W Scientific, Folsom, CA) emptied via a common tip positioned within 200 μm from the tip of the patch electrode in excised patch recordings and 400 μm from the cell under study in whole-cell recordings. Flow through each barrel was gravity fed and regulated by high-speed solenoid microvalves (The Lee Co., Westbrook, CT) operated by a programmable microprocessor-based controller. Switching between solutions occurred within <10 ms (seeDonevan et al., 1992). One barrel contained buffer and the others were filled with various drugs alone and in combination. Only one valve was open at a time, and the buffer solution was applied continuously between drug applications. In the single-channel recordings, drugs were applied for 15- to 60-s epochs, separated by 30- to 60-s wash periods.
In whole-cell voltage-clamp recordings from cultured rat hippocampal neurons, meprobamate enhanced GABA-evoked responses in a concentration-dependent manner with EC50 of 1.2 mM.
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN05CX01
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
||
|
DEA NO. |
2820
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
||
|
WHO-ATC |
N05CX01
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
||
|
WHO-ATC |
N05BC01
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
||
|
NCI_THESAURUS |
C29756
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
||
|
WHO-ATC |
N05BC51
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
||
|
NCI_THESAURUS |
C264
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
||
|
LIVERTOX |
NBK548721
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
||
|
WHO-VATC |
QN05BC01
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
||
|
WHO-VATC |
QN05BC51
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
4064
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
PRIMARY | |||
|
6760
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
PRIMARY | RxNorm | ||
|
m7199
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
PRIMARY | Merck Index | ||
|
1389008
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
PRIMARY | |||
|
57-53-4
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
PRIMARY | |||
|
7225
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
PRIMARY | |||
|
DTXSID3023261
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
PRIMARY | |||
|
DB00371
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
PRIMARY | |||
|
1704
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
PRIMARY | |||
|
Atovaquone and Proquanil
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
PRIMARY | |||
|
100000092826
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
PRIMARY | |||
|
Meprobamate
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
PRIMARY | |||
|
533
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
PRIMARY | |||
|
CHEMBL979
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
PRIMARY | |||
|
30418
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
PRIMARY | |||
|
9I7LNY769Q
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
PRIMARY | |||
|
C47603
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
PRIMARY | |||
|
3117
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
PRIMARY | |||
|
SUB08757MIG
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
PRIMARY | |||
|
D008620
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
PRIMARY | |||
|
200-337-5
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
PRIMARY | |||
|
MEPROBAMATE
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
PRIMARY | |||
|
9I7LNY769Q
Created by
admin on Mon Mar 31 17:54:26 GMT 2025 , Edited by admin on Mon Mar 31 17:54:26 GMT 2025
|
PRIMARY |
ACTIVE MOIETY